Should organs from hepatitis C-positive donors be used in hepatitis C-negative recipients for liver transplantation?

Liver Transpl. 2018 Jun;24(6):831-840. doi: 10.1002/lt.25072.

Abstract

Given the scarcity of donated organs and the frequency of death on the waiting list, strategies that could improve the available supply of high-quality liver grafts are much needed. Direct-acting antiviral agent (DAA) regimens have proved to be highly effective to treat hepatitis C virus (HCV), even in the setting of posttransplantation. The question arises as to whether transplant communities should consider the utilization of HCV-positive donors into HCV-negative recipients. This review summarizes risk of transmission, treatment options with success rate, and ethical considerations for usage of HCV-positive donors. Liver Transplantation 24 831-840 2018 AASLD.

Publication types

  • Review

MeSH terms

  • Allografts / surgery
  • Allografts / virology
  • Antiviral Agents / therapeutic use*
  • Donor Selection / standards*
  • End Stage Liver Disease / mortality
  • End Stage Liver Disease / surgery*
  • Hepacivirus / drug effects
  • Hepacivirus / isolation & purification
  • Hepatitis C / drug therapy
  • Hepatitis C / transmission*
  • Hepatitis C / virology
  • Humans
  • Liver / surgery
  • Liver / virology
  • Liver Transplantation / adverse effects
  • Liver Transplantation / standards*
  • Sustained Virologic Response
  • Tissue Donors / statistics & numerical data
  • Transplant Recipients / statistics & numerical data
  • Waiting Lists / mortality

Substances

  • Antiviral Agents